Dept. of Pharmacology, Institute of Post Graduate Medical Education and Research, 244 B, Acharya JC Bose Road, Kolkata-700 020, West Bengal, India.
Int Immunopharmacol. 2011 Nov;11(11):1668-79. doi: 10.1016/j.intimp.2011.08.002. Epub 2011 Aug 27.
Leishmaniasis is caused by protozoan parasites of the genus Leishmania and causes a wide spectrum of clinical manifestations ranging from self-healing cutaneous lesions to the fatal visceral form. The use of pentavalent antimony, the mainstay of therapy of Leishmaniasis is now limited by its toxicity and alarming increase in unresponsiveness, especially in the Indian subcontinent. Furthermore, other anti-leishmanial drugs are unaffordable in many affected countries and as vaccination based approaches have not yet proved to be effective, chemotherapy remains the only alternative, emphasizing the need for identifying novel drug targets. In this review, we have described the different host immune signaling pathways that could be considered as potential drug targets for Leishmania chemotherapy.
利什曼病是由利什曼原虫属的原生动物寄生虫引起的，其临床表现范围广泛，从可自行愈合的皮肤损伤到致命的内脏形式。目前，五价锑的应用，即利什曼病治疗的主要手段，受到其毒性和令人震惊的耐药性增加的限制，尤其是在印度次大陆。此外，许多受影响的国家都无法负担其他抗利什曼病药物，而且疫苗接种方法尚未被证明有效，因此化疗仍然是唯一的选择，这强调了需要确定新的药物靶点。在这篇综述中，我们描述了不同的宿主免疫信号通路，这些通路可以被认为是抗利什曼病化疗的潜在药物靶点。
